The performance of e23(Fv)PEs, recombinant toxins targeting the erbB-2 protein

Semin Cancer Biol. 1996 Apr;7(2):79-86. doi: 10.1006/scbi.1996.0012.

Abstract

The overexpression of the erbB-2 (HER-2, neu) gene has attracted significant interest as a molecular target for the rational design of cancer therapies. This review examines the design and preclinical testing phase for one such experimental therapy, recombinant toxins targeted to the erbB-2 protein, termed e23(Fv)PEs.

Publication types

  • Review

MeSH terms

  • ADP Ribose Transferases*
  • Animals
  • Antibodies
  • Antibody Formation
  • Bacterial Toxins / genetics
  • Drug Evaluation, Preclinical
  • Exotoxins / pharmacology
  • Humans
  • Immunotoxins / administration & dosage
  • Immunotoxins / immunology
  • Immunotoxins / pharmacology*
  • Immunotoxins / therapeutic use
  • Immunotoxins / toxicity
  • Macaca fascicularis
  • Mice
  • Neoplasms / drug therapy*
  • Pseudomonas aeruginosa / genetics
  • Pseudomonas aeruginosa Exotoxin A
  • Receptor, ErbB-2 / drug effects*
  • Receptor, ErbB-2 / immunology
  • Recombinant Fusion Proteins / therapeutic use
  • Recombinant Proteins / therapeutic use
  • Single-Chain Antibodies
  • Tumor Cells, Cultured
  • Virulence Factors*

Substances

  • Antibodies
  • Bacterial Toxins
  • Exotoxins
  • Immunotoxins
  • OLX 209
  • Recombinant Fusion Proteins
  • Recombinant Proteins
  • Single-Chain Antibodies
  • Virulence Factors
  • ADP Ribose Transferases
  • Receptor, ErbB-2